Ian B. Walters
Vice President and Chief Medical Officer
Dr. Walters has over 15 years of oncology/immunology drug development experience. Prior to joining Intensity Therapeutics, Dr. Walters spent seven years at Bristol-Myers Squibb (BMS), where he led clinical research and matrix development teams. During his tenure at BMS, he contributed to the development of multiple immuno-oncology products including the anti-CTLA-4 compound Impilimumab brand name Yervoy® and the anti-PD-1 compound, Nivolimumab brand name Opdivo®, as well as the licensing and partnering strategy for other immuno-oncologic agents.
Dr. Walters has worked in multiple biotech companies, including Millennium Pharmaceuticals, on corporate development, translational medicine, clinical development and medical affairs. Dr. Walters has also been a consultant to biotech, pharma and investment companies specializing in the evaluation, prioritization, and development of innovative technologies in the treatment of severe diseases. Before entering the private sector, Dr. Walters was a lead investigator at the Rockefeller University and initiated cutting-edge immunology research to understand the mechanism of action of several compounds. Dr. Walters received his MD from the Albert Einstein College of Medicine and an MBA from the Wharton School of the University of Pennsylvania.